Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7943716 | 0.89 | DGAT1 (0.37) | DGAT1KMT2ACYP2C19 | |
| SCHEMBL3141601 | 0.81 | DGAT1 (0.79) | DGAT1KMT2A | |
| SCHEMBL2597461 | 0.77 | TSHR (0.37) | KMT2ACYP2C19 | |
| SCHEMBL12306265 | 0.75 | HDAC6 (0.36) | DGAT1KMT2ACYP2C19 | |
| SCHEMBL1785142 | 0.74 | CYP2C19 (0.36) | KMT2ACYP2C19 | |
| SCHEMBL733594 | 0.74 | PRKCA (0.43) | KMT2ACYP2C19 | |
| SCHEMBL23293628 | 0.72 | ALDH1A1 (0.36) | KMT2ACYP2C19 | |
| Hydrogen Peroxide SCHEMBL28451976 | 0.72 | PRKCA (0.42) | KMT2ACYP2C19 | |
| SCHEMBL1735445 | 0.72 | DGAT1 (1.00) | DGAT1KMT2A | |
| SCHEMBL232414 | 0.71 | HTT (0.32) | KMT2ACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571862-B1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2014-04-16 | — | — | EP | disclosed |
| US-8436009-B2 | Prodrug of triazolone compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-07 | — | — | US | disclosed |
| EP-2571862-A1 | PRODRUG OF TRIAZOLONE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2011145747-A1 | PRODRUG OF TRIAZOLONE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053563-A1 | PRODRUG OF TRIAZOLONE COMPOUND | F7, TFPI, TFPI2 | DGAT1 3614/4885KMT2A 2484/4885CYP2C19 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.